Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Upstream Bio, Inc. (UPB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: UPB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $56.5
1 Year Target Price $56.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 22% | Avg. Invested days 41 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 407.33M USD | Price to earnings Ratio - | 1Y Target Price 56.5 |
Price to earnings Ratio - | 1Y Target Price 56.5 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 5.14 - 29.46 | Updated Date 06/28/2025 |
52 Weeks Range 5.14 - 29.46 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.36 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -3112.52% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 188616167 | Price to Sales(TTM) 184.56 |
Enterprise Value 188616167 | Price to Sales(TTM) 184.56 | ||
Enterprise Value to Revenue 85.46 | Enterprise Value to EBITDA - | Shares Outstanding 53596600 | Shares Floating 28482306 |
Shares Outstanding 53596600 | Shares Floating 28482306 | ||
Percent Insiders 19.81 | Percent Institutions 85.58 |
Analyst Ratings
Rating 2 | Target Price 56.5 | Buy 2 | Strong Buy 2 |
Buy 2 | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Upstream Bio, Inc.
Company Overview
History and Background
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies to address inflammatory and immunological (I&I) diseases. Founded in 2022, they are developing differentiated monoclonal antibodies (mAbs) to address unmet needs in I&I diseases.
Core Business Areas
- Drug Development: Focuses on researching and developing monoclonal antibody therapies for inflammatory and immunological diseases.
Leadership and Structure
Upstream Bio is led by CEO Jay Luly. The company has a management team with experience in drug development and immunology.
Top Products and Market Share
Key Offerings
- UPB-101: UPB-101 is Upstream Bio's lead product candidate, a monoclonal antibody designed to target the thymic stromal lymphopoietin receptor (TSLPR) to address a broad range of I&I diseases. Market share data for UPB-101 is unavailable, as it is still in clinical development. Competitors targeting similar pathways include Amgen and AstraZeneca, who are developing similar antibodies for TSLP.
Market Dynamics
Industry Overview
The biopharmaceutical industry is focused on developing new therapies for a wide range of diseases. The immunological space is very large, growing, and competitive.
Positioning
Upstream Bio is positioned as a clinical-stage company focused on novel mAbs for I&I diseases, aiming to develop differentiated therapies with significant unmet needs. Their competitive advantage lies in its novel target and lead compound UPB-101, that has a large potential market.
Total Addressable Market (TAM)
The total addressable market (TAM) for I&I therapies is substantial, estimated to be in the tens of billions of dollars annually. Upstream Bio aims to capture a portion of this market with its differentiated therapies.
Upturn SWOT Analysis
Strengths
- Novel target
- Experienced management team
- Strong investor backing
- Lead compound UPB-101 showing promise
Weaknesses
- Clinical-stage company with no approved products
- Reliance on success of UPB-101
- High cash burn rate
- Limited pipeline
Opportunities
- Successful clinical trials for UPB-101
- Expansion of pipeline with new drug candidates
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger pharmaceutical company
Threats
- Clinical trial failures
- Competition from other I&I therapies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- AMGN
- AZN
Competitive Landscape
Upstream Bio faces competition from established pharmaceutical companies with approved I&I therapies and other companies developing novel therapies in the same space. Upstream bio is private and has no market share, its competitors have much larger market share.
Growth Trajectory and Initiatives
Historical Growth: Upstream Bio's growth is currently focused on the clinical development of UPB-101.
Future Projections: Future growth depends on the successful clinical development and commercialization of UPB-101 and other pipeline candidates.
Recent Initiatives: Advancing UPB-101 through clinical trials.
Summary
Upstream Bio is a clinical-stage company with a promising lead compound targeting a novel pathway in I&I diseases. The company is focused on UPB-101's clinical development, and success hinges on its clinical trial outcomes. A limited pipeline and high cash burn rate pose key risks. Securing partnerships or potential acquisition by a larger player could be beneficial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Analyst Reports
- Clinical Trial Data
Disclaimers:
This analysis is based on publicly available information and represents an opinion. It is not financial advice, and readers should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Upstream Bio, Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2024-10-11 | CEO & Director Dr. E. Rand Sutherland M.D., M.P.H., MPH | ||
Sector Healthcare | Industry Biotechnology | Full time employees 52 | Website https://upstreambio.com |
Full time employees 52 | Website https://upstreambio.com | ||
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. Its product candidate includes verekitug, which is in Phase 2 clinical development for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps, as well as in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.